Comparison of Clomiphene Citrate and Letrozole for Ovulation Induction in Polycystic Ovary Syndrome
Objective: To compare mean number of mature follicles and endometrial thickness in infertile patients having polycystic ovarian syndrome receiving clomiphene citrate and letrozole.
Design: It was a randomized controlled trial.
Study Settings: This study was carried out at Department of Obstetrics and Gynecology, Combined Military Hospital Muzaffarabad over 6 months from December 2015 to May 2016.
Material and Methods: This study involved 60 women aged between 18-35 years presenting with infertility and diagnosed of PCOS. Two treatment groups were made by random division of the patients. Patients of Group-A were given letrozole while clomiphene citrate was given to the patients of Group-B. Mean number of mature follicles and mean endometrial thickness were the variables used for measuring outcomes in both the groups. An informed written consent was taken from all the patients. A predesigned proforma was used to record patient’s demographic details along with case outcome.
Results: The patients had mean age of 25.75±5.38 years while the mean duration of infertility was 3.17±1.98 years. The mean number of mature follicles (2.83±0.79 vs. 2.10±0.71; p=0.000) was significantly higher but the mean endometrial thickness (7.40±1.87mm vs. 9.17±1.86mm; p=0.001) were significantly lower with letrozole as compared to clomiphene citrate and this difference was significant across all age and duration of infertility groups.
Conclusion: We observed that in infertile patients with PCOS, letrozole was associated with significantly higher mean number of mature follicles with significantly lower mean endometrial thickness as compared to clomiphene citrate. Thus letrozole should be preferred in the management of infertility with PCOS as it would increase the likelihood of pregnancy.
Copyright (c) 2018 Journal of the Society of Obstetrics and Gynaecologists of Pakistan
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.